RxDoctor Payments Data

Scott Roberts, MD

Pulmonary Disease · Indianapolis, INNPI 1982605044

Payments from drug & device makers

$1,577in general payments, 2019–2025

Across 27 payments — averaging $58.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$890
  • Boston Scientific$166
  • Haemonetics Corporation$114
  • Takeda Pharmaceuticals U.S.A., Inc.$87
  • Sanofi$50
  • Regeneron Healthcare Solutions, Inc.$49
  • plus $222 from 6 others

What the payments were for

  • Travel & lodging$89056%
  • Food & beverage$63941%
  • Education$483%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,577 in reported general payments places this provider in the 40th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$45,737
Medicare patients
174
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$112,928
Dupixent PenDupilumab13$53,129
XolairOmalizumab24$51,489
Breo ElliptaFluticasone/Vilanterol73$37,050
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$19,140
Advair HfaFluticasone Propion/Salmeterol15$6,363
Albuterol Sulfate HfaAlbuterol Sulfate181$5,266
Fluticasone Propionate HfaFluticasone Propionate15$4,931
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate15$4,027
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,995
Ventolin HfaAlbuterol Sulfate18$1,272
Montelukast Sodium87$746
Azithromycin35$668
Fluticasone Propionate31$424
Doxycycline Monohydrate13$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere$41$19,14021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →